Skip to main content
SpringerLink
Log in
Book cover

Arterielle Hypertonie pp 453–472Cite as

Klinische Pharmakologie der antihypertensiven Pharmakotherapie

  • Chapter

Zusammenfassung

Dem Symptomenkreis „Hochdruckkrankheit“ liegen unterschiedliche Ursachen zugrunde. Während einige der sekundären Hypertonieformen kausal behandelt werden können, ist man bei der primären oder essentiellen Hypertonie ausschheßlich auf die symptomatische Therapie durch blutdrucksenkende Medikamente angewiesen, sofern sich durch Umstellungen in der Lebensweise, z. B. Reduktion der Kochsalzzufuhr u. a. m., nicht die gewünschte Blutdrucksenkung herbeiführen läßt. Die Hoffnung, je nach Ätiologie des Hochdrucks beim einzelnen Patienten gezielt bestimmte Wirkstoffe einsetzen zu können, hat sich bisher nicht erfüllt.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abboud FM, Eckstein JW, Wendling MG (1962) Early potentiation of the vasoconstrictor action of norepinephrine by guanethidine. Proc Soc Exp Biol Med 110:489–492

    PubMed  CAS  Google Scholar 

  2. Ablad B, Johnsson G (1963) Comparative effects of intra-arterially administered hydralazine and sodium nitrite on blood flow and volume of forearm. Acta Pharmacol Toxicol (Kbh) 20: 1–15

    CAS  Google Scholar 

  3. Ablad B, Carlsson E, Dahlöf C, Ek L (1976) Some aspects of the pharmacology of ß-adreno- ceptor blockers. Drugs (Suppl 1) 11:100–111

    Google Scholar 

  4. Anavekar SN, Louis WJ, Morgan TP, Doyle AE, Johnston CI (1975) The relationship of plasma levels of pindolol in the hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clin Pharmacol Exp Physiol 2:203–212

    Article  CAS  Google Scholar 

  5. Anderson J, Godfrey BE, Hill DM, Munro- Faure AD, Sheldon J (1971) A comparsion of the effects of hydrochlorothiazide and of fruse- mide in the treatment of hypertensive patients. Q JMed NS 10:541–560

    Google Scholar 

  6. Andersson R (1973) Cyclic AMP as a mediator of the relaxing action of papaverine, nitroglycerine, diazoxide and hydralazine in intestinal and vascular smooth muscle. Acta Pharmacol Toxicol (Kbh) 32:321–336

    Article  CAS  Google Scholar 

  7. Armstrong B, Stevens N, Doll R (1974) Retrospective study of the association between use of Rauwolfia derivatives and breast cancer in English women. Lancet II: 672–675

    Article  Google Scholar 

  8. Arnold OH (1970) Therapie der arteriellen Hypertonie. Springer, Berlin Heidelberg New York S85, 87

    Book  Google Scholar 

  9. Ayvazian JH, Ayvazian LF (1961) Study of hy- peruricaemia induced by hydrochlorothiazide and acetolamide separately and in combination. J Clin Invest 40:1961–1966

    Article  PubMed  CAS  Google Scholar 

  10. Bertler A (1961) Effect of reserpine on the storage of catecholamines in brain and other tissues. Acta Physiol Scand 51:75–83

    Article  CAS  Google Scholar 

  11. Beumer HM, Hardonk HJ (1972) Effects of beta-adrenergic blocking drugs on ventilatory function in asthmatics. Eur J Clin Pharmacol 5:77–80

    Article  CAS  Google Scholar 

  12. Boakes AJ, Knight EJ, Prichard BNC (1971) Preliminary studies of the pharmacological effects of 5(l-hydroxy-2(l-methyl-3-phenylpro- pyl)amino-ethyl)syhcylamide(AH 5158) in man. Clin Sci 40:18

    Google Scholar 

  13. Bolme P, Fuxe K (1971) Pharmacological studies on the hypotensive effects of Clonidine. Eur J Pharmacol 13:168–174

    Article  PubMed  CAS  Google Scholar 

  14. Borhani NO (1960) Chlorothiazide and hydrochlorothiazide. A comparative study of their hypotensive, saluretic and hyperuricemic action. Ann Intern Med 53:342–358

    PubMed  CAS  Google Scholar 

  15. Bravo EL, Tarazi RC, Dustan HP (1974) On the mechnism of suppressed plasma renin activity during beta-adrenergic blockade with propranolol. J Lab Clin Med 83:119–128

    PubMed  CAS  Google Scholar 

  16. Bravo EL, Tarazi RC, Dustan HP (1975) Beta- adrenergic blockade in diuretic-treated patients with essential hypertension. N Engl J Med 292:66–70

    Article  PubMed  CAS  Google Scholar 

  17. Bravo EL, Tarazi RC, Dustan HP, Lewis JW (1975) Dissociation between renin and arterial pressure responses to beta-adrenergic blockade in human essential hypertension. Circ Res (Suppl I) 36/37:241–247

    PubMed  CAS  Google Scholar 

  18. Brodie BB, Chang CC, Costa E (1965) On the mechanism of action of guanethidine and brety- lium. Br J Pharmacol 25:171–178

    CAS  Google Scholar 

  19. Brogden RN, Heel RC, Speight TM, Avery GS (1977) Prazosin: A review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14:163–197

    Article  PubMed  CAS  Google Scholar 

  20. Bühler FR, Laragh JH, Baer L, Vaughan E, Brunner HR (1972) Propranolol inhibition of renin secretion. N Engl J Med 287:1209–1214

    Article  PubMed  Google Scholar 

  21. Cairns SA, Jordan SC (1976) Prazosin treatment complicated by acute febrile polyarthritis. Br Med J II: 1424–25

    Article  Google Scholar 

  22. Cambridge D, Davey MJ, Massingham R (1977) Prazosin a selective antagonist of postsynaptic a-adrenoceptors. Br J Pharmacol 59:514P- 515P

    PubMed  CAS  Google Scholar 

  23. Carstairs KD, Breckenridge A, Dollery CT, Worlledge SM (1966) Incidence of a positive direct Coombs test in patients on a-methyldopa. Lancet 11:133–135

    Article  Google Scholar 

  24. Cass R, Spriggs TLB (1961) Tissue amine levels and sympathetic blockade after guanethidine and bretylium. Br J Pharmacol 17:442–450

    CAS  Google Scholar 

  25. Chamberiain DA, Howard J (1964) Guanethidine and methyldopa: A hemodynamic study. Br Heart J 26:528–536

    Article  Google Scholar 

  26. Chang CC, Costa E, Brodie BB (1965) Interaction of guanethidine with adrenergic neurons. J Pharmacol Exp Ther 147:303–312

    PubMed  CAS  Google Scholar 

  27. Chaterjee K, Parmley WW, Ganz W, Forrester J, Walinsky P, Crexels C, Swan HJC (1973) Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction. Circulation 48:1183–1193

    Google Scholar 

  28. Chidsey CA (1973) Clinical and pharmacokinetic studies of minoxidil, a new antihypertensive agent. Chn Sci Mol Med (Suppl I) 45:171–173

    Google Scholar 

  29. Chidsey CA, Braunwald E, Morrow AG, Mason DT (1963) Myocardial norepinephrine concentration in man. Effects of reserpine and of congestive heart failure. N Engl J Med 269: 653–658

    Article  PubMed  CAS  Google Scholar 

  30. Cohen SI, Young MW, Lau SH, Haft JI, Damato AN (1968) Effects of reserpine therapy on cardiac output and atrioventricular conduction during rest and controlled heart rates in patients with essential hypertension. Circulation 37: 738–746

    PubMed  CAS  Google Scholar 

  31. Cohn JN, Liptak TE, Freis ED (1963) Hemodynamic effects of guanethidine in man. Circ Res 12:298–307

    PubMed  CAS  Google Scholar 

  32. Collier JG, Dawnay NAH, Nachev Ch, Robinson BF (1972) Clinical investigation of an antagonist at a- and ß-adrenoceptors — AH 5158A. Br J Pharmacol 44:286–293

    PubMed  CAS  Google Scholar 

  33. Connolly CK, Batten JC (1970) Comparsion of the effect of alprenolol and propranolol on specific airway conductance in asthmatic subjects. Br Med J 2:515–516

    Article  PubMed  CAS  Google Scholar 

  34. Conolly ME, Oates JA (1977) IV. Clonidine. In: Oates JA, Conolly ME, Prichard BNC, Shand DG, Schapel G (eds) The Clinical pharmacology of antihypertensive drugs. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol XXIX, pp583- 589)

    Google Scholar 

  35. Constantine JW, McShane WK, Scriabine A, Hess HJ (1973) Analysis of the hypotensive action of prazosin. In: Onesti G, Kün KE, Moyer JH (eds) Hypertension: Mechanismus and management. The 26th Hahnemann Symposium, Grune & Stratton, New York London, pp 429–444

    Google Scholar 

  36. Conway J (1977) Antihypertensive effect of diuretics. In: Gross F (ed) Antihypertensive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol XXXIX, pp 477–497)

    Google Scholar 

  37. Conway J, Lauwers P (1960) Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation 21:21–27

    PubMed  CAS  Google Scholar 

  38. Cranston WI, Juel-Jensen BE, Semmence AM, Jones RPCH, Forbes JA, Mutch LMM (1963) Effect of oral diuretics on raised arterial pressure. Lancet 11:966–970

    Article  Google Scholar 

  39. Dargie HJ, Dollery CT, Daniel J (1976) Labetalol in resistant hypertension. Br J Clin Pharmacol (Suppl 3) 3:751–755

    PubMed  CAS  Google Scholar 

  40. Davidov M, Kakaviatos N, Finnerty FA Jr (1967) The antihypertensive effects of an imidazoline compound (Catapres). A preliminary chnical and hemodynamic evaluation in man. Clin Pharmacol Ther 8:810–816

    PubMed  CAS  Google Scholar 

  41. Davies DS, Wing LMH, Reid JL, Neül E, Tip- pett P, Dollery CT (1977) Pharmacokinetics and concentration-effect relationships of intravenous and oral Clonidine. Clin Pharmacol Ther 21:593–601

    PubMed  CAS  Google Scholar 

  42. Day MD, Owen AA, Warren PR (1968) An adrenergic neuron blocking action of propranolol in isolated tissues. J Pharmacol (Lond) 20:1305–1345

    Google Scholar 

  43. Dixit BN, Gulati GD, Gokhale SD (1961) Action of bretylium and guanethidine at the neuromuscular junction. Br J Pharmacol 17:372

    CAS  Google Scholar 

  44. Dollery CT, Davies DS, Draffan GH, Dargie JH, Dean CR, Reid JL, Clare RA, Murray S (1975) Clinical pharmacology and pharmacokinetics of Clonidine. Clin Pharmac Ther 19: 11–17

    Google Scholar 

  45. Draffan GH, Clare RA, Murray S, Bellward GD, Davies DS, Dollery CT (1975) The determination of Clonidine in human plasma. Proc. of the Third Int. Symp. on Mass Spectrometry in Biochemistry and Medicine, Sardinia, Italy, June 1975.

    Google Scholar 

  46. Davies DS, Wing LMH, ReidJL, NeihE, TippettP, Dollery CT (1977) Pharmacokinetics and concentration-effect relationships of intravenous and oral Clonidine. Chn Pharmacol Ther 21:593–601

    CAS  Google Scholar 

  47. Dustan HP, Tarazi RC, Bravo EL (1972) Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Engl JMed 286:861–866

    Article  PubMed  CAS  Google Scholar 

  48. Editorial (1975) Prazosin and sudden collapse. Lancet 1:645

    Google Scholar 

  49. Elkington SG, Schreiber WM, Conn HO (1969) Hepatic injury caused by L-alpha-methyldopa. Circulation 40:589–595

    PubMed  CAS  Google Scholar 

  50. Euler US von, Lishajko F (1963) Effect of reserpine on the uptake of catecholamines in isolated nerve storage granules. Int J Neuropharmacol 2:127–134

    Article  Google Scholar 

  51. Farmer JB, Kennedy I, Levy GP, Marshall RJ (1972) Pharmacology of AH 5158; a drug which blocks both a- and ß-adrenoceptors. Br J Pharmacol 45:660–675

    PubMed  CAS  Google Scholar 

  52. Fernandes M, Smith IS, Sanford I, Weder A, Kim KE, Gould AB, Busby P, Swartz C, Onesti G (1975) Prazosin in the treatment of hypertension. Clin Sci Mol Med (Suppl 2) 48: 181s-184s

    Google Scholar 

  53. Fitzgerald JD (1970) Perspectives in adrenergic beta-receptor blockade. Clin Pharmacol Ther 10:292–306

    Google Scholar 

  54. Formgren H, Eriksson ME (1975) Effects of practolol in combination with terbutaline in the treatment of hypertension and arrhythmias in asthmatic patients. Scand J Respir Dis 56: 217–222

    PubMed  CAS  Google Scholar 

  55. Franciosa JA, Freis ED (1975) Normal cardiac output during beta-blockade with timolol in hypertensive patients. Clin Pharmacol Ther 18: 158–164

    PubMed  CAS  Google Scholar 

  56. Freis ED (1965) Guanethidine. Prog Cardiovasc Dis 8:183–193

    Article  PubMed  CAS  Google Scholar 

  57. Freis ED, Rose JC, Higgins TF, Finnerty FA Jr, Kelley RT, Partenope EA (1953) The hemodynamic effects of hypotensive drugs in man. IV. 1-hydrazinophthalazine. Circulation 8:199–204

    PubMed  CAS  Google Scholar 

  58. Freis ED, Sappington RF (1966) Long-term effect of probenecid on diuretic-induced hyper- uricaemia. JAMA 198:127–129

    Article  PubMed  CAS  Google Scholar 

  59. Freis ED, Wanko A, Schnaper HW, Frohlich ED (1960) Mechanism of the altered blood pressure responsiveness produced by chlorothiazide. J Clin Invest 39:1277–1281

    Article  PubMed  CAS  Google Scholar 

  60. Frick MH, Pörsti P (1976) Combined alpha- and beta-adrenoceptor blockade with labetalol in hypertension. Br Med J 1:1046–1048

    Article  PubMed  CAS  Google Scholar 

  61. Frohlich ED, Tarazi RC, Dustan HP, Page IH (1968) The paradox of beta-adrenergic blockade in hypertension. Circulation 37:417–423

    PubMed  CAS  Google Scholar 

  62. Frohlich ED, Thurman AE, Pfeffer MA, Brob- mann GF, Jacobson ED (1972) Altered vascular responsiveness: initial hypotensive mechanism of thiazide diuretics. Proc Soc Exp Biol Med 140:1190–1196

    PubMed  CAS  Google Scholar 

  63. Giudicelh JF, Lhoste F, Boissier JR (1975) ß- adrenergic blockade and atrio-ventricular conduction impairment. Eur J Pharmac 31: 216–225

    Article  Google Scholar 

  64. Prichard BNC, Thompson FO, Boakes AJ, Joekes AM (1975) Some haemodynamic effects of compound AH5158 compared with propranolol, propranolol plus hydralazine, and diazoxide: the use of AH5158 in the treatment of hypertension. Clin Sci Mol Med 48:97s-100s

    Google Scholar 

  65. Goldstein GB, Lam KC, Mistilis SP (1973) Drug-induced active chronic hepatitis. Am J Dig Dis 18:177–184

    Article  PubMed  CAS  Google Scholar 

  66. Gottheb TB, Thomas RC, Chidsey CA (1972) Pharmacokinetik studies of minoxidil. Clin Pharmacol Ther 13:436–441

    Google Scholar 

  67. Graham RM, Muir MR, Hayes JM (1976) Differing effects of the vasodilator drugs, prazosin and diazoxide on plasma renin activity in the dog. Clin Exp Pharmacol and Psysiol 3:1–5

    Article  Google Scholar 

  68. Graubner W, Wolf M (1966) Kritische Betrachtungen zum Wirkungsmechanismus des 2 (2,6- dichlorophenyl-amino)-2-imidazolin-hydro- chlorid. Arzneim Forsch 16:1055–1058

    CAS  Google Scholar 

  69. Gross F (1977) Antihypertensive drugs. In: Gross F (ed) Antihypertensive agents. Springer, Berlin Heidelberg New York (Handbook of ex- perimental pharmacology, vol XXXIX, pp 1- 11)

    Google Scholar 

  70. Gross F (1977) Drugs acting on arteriolar smooth muscle (vasodilator drugs). In: Gross F (ed) Antihypertensive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol XXXIX, pp 397- 476)

    Google Scholar 

  71. Hansson L, Hunyor SN, Julius S, Hoobler SW (1973) Blood pressure crisis following withdrawal of Clonidine with special reference to arterial and urinary catecholamine levels and suggestions for acute management. Am Heart J 85:605–610

    Article  PubMed  CAS  Google Scholar 

  72. Hansson L, Zweifler AJ (1974) The effect of propranolol on plasma renin activity and blood pressure in mild essential hypertension. Acta Med Scand 195:397–401

    Article  PubMed  CAS  Google Scholar 

  73. Heidenreich O (1977) Moderne pharmazeutische Aspekte der Diuretika Therapie. In: Finger GH (Hrsg) 25 Jahre Diuretika. Symposion Hamburg 1976. Merck/Sharp & Dohme, München, S 21–29

    Google Scholar 

  74. Heinonen OP, Shapiro S, Tuominen L, Turunen MI (1974) Reserpine use in relation to breast cancer. Lancet 11:675–677

    Article  Google Scholar 

  75. Heise A, Kroneberg G (1972) Alpha-sympathetic receptor Stimulation in the brain and hypotensive activity of alpha-methyldopa. Eur J Pharmacol 17:315–317

    Article  PubMed  CAS  Google Scholar 

  76. Henning M (1975) Central action of alpha-methyldopa. In: Davies J, Reid lA (eds) Central action of drugs in blood pressure regulation. University Park Press, Baltimore, pp 157–165

    Google Scholar 

  77. Hertting G, Axelrod J, Patrick RW (1962) Actions of bretylium and guanethidine on the uptake and release of (3H)-noradrenaline. Br J Pharmacol 18:161–166

    CAS  Google Scholar 

  78. Hess HJ (1974) Biochemistry and structure-ac- tivity studies with prazosin. In: Cotton DWK (ed) Proceedings of a Symposium held at the Centre Interprofessionnel, Geneva, March 8, 1974. Elsevier, New York, pp3–15

    Google Scholar 

  79. Hökfeh B, Hedeland H, Dymling JF (1970) Studies on catecholamines, renin and aldosterone foUowing Catapresan (2-(2,6-dichloro- phenyl-amine)-2-imidazoline hydrochloride) in hypertensive patients. Eur J Pharmacol 10: 389–397

    Article  Google Scholar 

  80. Holhfield JW, Sherman K, Zwagg R van der, Shand DG (1976) Proposed mechanisms of propranolol’s antihypertensive effect in essential hypertension. N Engl J Med 295:68–73

    Article  Google Scholar 

  81. Holzbauer M, Vogt M (1956) Depression by reserpine of the noradrenaline concentration in the hypothalamus of the cat. J Neurochem 1:8–11

    Article  PubMed  CAS  Google Scholar 

  82. Hugues FC, Julien D, Muñera Y, Marche J (1974) Médicaments béta-adrénolytiques et vendlation. I. Comparaison des effects béta-blo- quants du propranolol et du practolol. Thérapie 29:201–210

    PubMed  CAS  Google Scholar 

  83. Jick H, Slone D, Shapiro S, Heinonen OP (1974) Reserpine and breast cancer. Lancet 11:669–671

    Google Scholar 

  84. Johnsson G, Svedmyr M, Thirmger G (1975) Effects of intravenous propranolol and meto- prolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics. Eur J Chn Pharmacol 8: 175–180

    Article  CAS  Google Scholar 

  85. Kane J, Gregg I, Richards DA (1976) A double- blind trial of labetalol. Br J Clin Pharmacol (Suppl 3) 3:737–741

    PubMed  CAS  Google Scholar 

  86. Kaufmann JF, Feagin OT, Shand DG, McAllister RG, Payne NA, Oates JA (to be published) Guanethidine and related agents. IV: Kinetic characterization of the pool of drug stored in human adrenergic neuron.

    Google Scholar 

  87. Oates JA, Conolly ME, Prichard BNC, Shand DG, Schapel G (1977) The chnical pharmacology of antihypertensive drugs. In: Gross F (Hrsg) Antihypertensive agents. Springer, Berlin Heidelberg New York (Handbuch der experimentellen Pharmakologie, BdXXXDC) S 571–632

    Google Scholar 

  88. Kennedy I, Levy GP (1975) Combined a- and ß-adrenoceptor blocking drug AH 5158: further studies on ’-adrenoceptor blockade in anaesthetized animals. Br J Pharmacol 53:585–592

    PubMed  CAS  Google Scholar 

  89. Kewitz H, Jesdinsky JH, Schröter P-M, Lindtner E (1977) Reserpine and breast cancer in women in Germany. Eur J Clin Pharmacol 11:79–83

    Article  PubMed  CAS  Google Scholar 

  90. Kirshner N (1962) Uptake of catecholamines by a particulate fraction of the adrenal medulla. J Biol Chem 237:2311–2317

    PubMed  CAS  Google Scholar 

  91. Koch G (1976) Haemodynamic effects of combined alpha- and ß-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise. Br J Clin Pharmacol (Suppl 3) 3:725–728

    PubMed  CAS  Google Scholar 

  92. Kohner EM, Dollery CT, Lowy C, Schumer B (1971) Effect of diuretic therapy on glucose tolerance in hypertensive patients. Lancet I: 986–990

    Article  Google Scholar 

  93. Koshy MC, Mickley D, Bourgoignie J, Blaufox MD (1977) Physiologic evaluation of a new antihypertensive agent. Prazosin HCl. Circulation 55:533–537

    PubMed  CAS  Google Scholar 

  94. Kroneberg G, Stoepel K (1962) Über eine Wirkung von Guanethidin auf Skelettmuskulatur und Rückenmarkreflexe. Naunyn-Schmiedebergs Arch Pharmacol 243:36

    CAS  Google Scholar 

  95. Kwan KC, Foltz EL, Breauh GO, Baer JE, Totaro JA (1976) Pharmacokinetics of methyldopa in man. J Pharmacol Exp Ther 198:264–277

    PubMed  CAS  Google Scholar 

  96. Larbi E, Zaimis E (1970) The effect of the chronic administration of Clonidine (St 155) on vascular smooth muscle. Br J Pharmacol 39: 221P

    Google Scholar 

  97. Laska EM, Siegel C, Meisner M, Fischer S, Wanderling J (1975) Matched-pairs study of reserpine use and breast cancer. Lancet II: 296–300

    Article  Google Scholar 

  98. Leonetti G, Mayer G, Morganti A, Ferzoh I, Zanchetti A, Banchetti G, Salle E di, Morselli PL, Chidsey CA (1975) Hypotensive and renin- suppressing activities of propranolol in hypertensive patients. Clin Sci Mol Med 48: 491–499

    CAS  Google Scholar 

  99. Lewis PJ (1975) Propranolol — an antihypertensive drug with a central action. In: Davies J, Reid IA (eds) Central action of drugs in blood pressure regulation. University Park Press, Baltunore, pp 206–224

    Google Scholar 

  100. Limas CJ, Freis ED (1973) Minoxidü in severe hypertension with renal failure. Effect of its addition to conventional antihypertensive drugs. Am J Cardiol 31:355–361

    Article  PubMed  CAS  Google Scholar 

  101. Lloyd-Mostyn RH, Oram S (1975) Modification by propranolol of cardiovascular effects of induced hypoglycaemia. Lancet II: 1213–1217

    Article  Google Scholar 

  102. Lund-Johansen P (1970) Hemodynamic changes in long-term diuretic therapy of essential hypertension. Acta Med Scand 187: 509–518

    Article  PubMed  CAS  Google Scholar 

  103. Lund-Johansen P (1974) Hemodynamic changes at rest and during exercise in long-term prazosin therapy of essential hypertension. In: Cotton DWK (ed) Prazosin, evaluation of a new anti-hypertensive agent. Excerpta Medica, Amsterdam, pp 43–51

    Google Scholar 

  104. Lydtin H, Kusus T, Daniel W, Schieri W, Ackenheil M, Kempter H, Lohmoller G, Miklas M, Walter I (1972) Propranolol therapy in essential hypertension. Am Heart J 83:589–595

    Article  PubMed  CAS  Google Scholar 

  105. Mack TM, Henderson BE, Gerkins VR, Arthur M, Baptista J, Pike MC (1975) Reserpine and breast cancer in a retirement community. N Engl JMed 292:1366–1370

    Article  CAS  Google Scholar 

  106. Marshall A, Roberts CJC, Barritt DW (1976) A study of cold extremities in patients taking beta- blocking drugs. Drugs 12:412–441

    Article  Google Scholar 

  107. Masoni A, Tommasi AM, Baggioni F, Bagni B (1974) Hemodynamic study in man of medium- term treatment with a new amino-quinazoline antihypertensive agent. In: Cotton DWK (ed) Prazosin, evaluation of a new anti-hypertensive agent. Excerpta Medica, Amsterdam, pp 54–63

    Google Scholar 

  108. McLeod VH (1972) The influence of some centrally acting drugs on sympathetic nerve activity. Br J Pharmacol 45:194P-195P

    Google Scholar 

  109. McMartin C, Rondel NB, Vinter J, Allan BR, Humberstone NB, Leishman AWD, Sandler G, Thirkettle JL (1970) The fate of guanethidine in two hypertensive patients. Clin Pharmacol Ther 11:423–431

    PubMed  CAS  Google Scholar 

  110. Mendlowitz M, Naftchi N, Gitlow SE, Weinrer L, Wolf RL (1960) The effect of chlorothiazide and its congeners on the digital circulation in normotensive subjects and in patients with essential hypertension. Ann NY Acad Sci 88: 964–974

    Article  PubMed  CAS  Google Scholar 

  111. Michelakis AN, McAlhster RG (1972) The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Chn Endocrinol Metab 34:386–394

    Article  CAS  Google Scholar 

  112. Miller RR, Awan NA, Maxweh KS, Mason DT (1977) Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilatator prazosin. N Engl J Med 297:303–307

    Article  PubMed  CAS  Google Scholar 

  113. Miller RR, Vismara LA, Zelis R, Amsterdam EA, Mason DT (1975) Clinical use of sodium nitroprusside in chronic ischemic heart disease. Effects on peripheral vascular resistance and venous tone and on ventricular volume, pump and mechanical performance. Circulation 51:328–336

    PubMed  CAS  Google Scholar 

  114. Mitcheh JR, Oates JA (1970) Guanethidine and related agents. I. Mechanism of the selective blockade of adrenergic neurons and its antagonism by drugs. J Pharmacol Exp Ther 172: 100–107

    Google Scholar 

  115. Molnar GW, Read RC (1974) Propranolol enhancement of hypoglycemic sweating. Clin Pharmacol Ther 15:490–496

    PubMed  CAS  Google Scholar 

  116. Mookerjee S, Eich RH, Obeid AI, Smulyan H (1977) Hemodynamic and plasma renin effects of propranolol in essential hypertension. Arch Intern Med 137:290–295

    Article  Google Scholar 

  117. Morgan TO, Roberts R, Carney SL, Louis WJ, Doyle AE (1975) ß-adrenergic receptor blocking drugs, hypertension and plasma renin. Br J Clin Pharmacol 2:159–164

    PubMed  CAS  Google Scholar 

  118. Muir AL, Burton JL, Lawrie DM (1969) Circulatory effects at rest and exercise of Clonidine, an hnidazoline derivative with hypotensive properties. Lancet 11:181–185

    Article  Google Scholar 

  119. Mülheims GH, Brown GO (1962) Effect of guanethidine on blood volume in essential hypertension. Proc Soc Exp Biol Med 109: 613–615

    Google Scholar 

  120. Muscholl E, Maitre I (1964) Release by sympathetic stimulation of a-methylnoradrenaline stored in the heart after administration of a-me- thyldopa. Experientia 19:658–659

    Article  Google Scholar 

  121. Myhre E, Brodwa UEK, Stenbaek O, Hansen T (1972) Plasma turnover of methyldopa in advanced renal failure. Acta Med Scand 191: 343–347

    PubMed  CAS  Google Scholar 

  122. Niarchos AP, Tarazi RC (1976) Hemodynamic effects of beta-adrenergic blocking agents in hypertension. In: Onesti G, Fernandes M, Kim KE (eds) Regulation of blood pressure by the central nervous system. Grune & Stratton, New York London, pp 397–409

    Google Scholar 

  123. Nies AS, Shand DG (1975) Clinical pharmacology of propranolol. Circulation 52:6–51

    PubMed  CAS  Google Scholar 

  124. O’Fallon WM, Labarthe DR, Kurland LT (1975) Rauwolfia derivatives and breast cancer. Lancet II: 292–300

    Article  Google Scholar 

  125. Perry HM Jr (1973) Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med 54:58–72

    Article  PubMed  Google Scholar 

  126. Philippu A, Schümann HJ (1962) Der Einfluß von Guanethidin und Bretyhum auf die Freisetzung von Brenzkatechinaminen. Naunyn- Schmiedebergs Arch Pharmacol 243:26–35

    CAS  Google Scholar 

  127. Pitts NE (1974) The clinical evaluation of prazosin hydrochloride, a new antihypertensive agent. In: Cotton DWK (ed) Prazosin, evaluation of a new anti-hypertensive agent. Excerpta Medica, Amsterdam, pp 149–163

    Google Scholar 

  128. Pletscher A, Shore PA, Brodie BB (1956) Serotonin as a mediator of reserpine action in brain. J Pharmacol Exp Ther 116:84–89

    PubMed  CAS  Google Scholar 

  129. Plummer AJ, Yonkman FF (1960) The influence of antihypertensive and hypertensive substances on vascular reactivity to catecholamines. Am J Cardiol 5:640

    Article  PubMed  CAS  Google Scholar 

  130. Prichard BNC (1964) Hypotensive action of pronethalol. Br Med J 1:1227–1228

    Article  PubMed  CAS  Google Scholar 

  131. Prichard BNC, Gillam PMS (1964) The use of propanolol in the treatment of hypertension. Brit Med J 11:725–727

    Article  Google Scholar 

  132. Putzeys MR, Hoobler SW (1972) Comparison of Clonidine and methyldopa on blood pressure and side effects in hypertensive patients. Am Heart 183:464–468

    Article  Google Scholar 

  133. Rahn KH, Goldberg L (1969) Comparison of antihypertensive efficacy, intestinal absorption and excretion of guanethidine in hypertensive patients. Clm Pharmacol Ther 10:858–866

    CAS  Google Scholar 

  134. Rand MJ, Jurevics H (1977) The pharmacology of rauwolfia alkaloids. In: Gross F (ed) Antihypertensive agents. Springer, Berlin Heidelberg New York (Handbook of experimental pharmacology, vol XXXIX) pp 77–159

    Google Scholar 

  135. Richards DA, Woodings EP, Stephens MDB, Maconochie JG (1974) The effects of oral AH 5158, a combined a- and ß-adrenoceptor antagonist, in healthy volunteers. Br J Clin Pharmacol 1:505–510

    CAS  PubMed  Google Scholar 

  136. Richards DA, Maconochie JG, Bland RE, Hopkins R, Woodings EP, Martin LE (1977) Relationship between plasma concentrations and pharmacological effects of labetolol. Eur J Clin Pharmacol 11:85–90

    Article  PubMed  CAS  Google Scholar 

  137. Richardson DW, Wyso EM, Magee JH, Caveh GC (1960) Circulatory effects of guanethidine: Clinical renal and cardiac responses to treatment with a novel antihypertensive drug. Circulation 22:184–190

    CAS  Google Scholar 

  138. Rowe GC, Huston JH, Maxweh GM, Crosley AP, Crumpton CW (1955) Hemodynamic effects of 1-hydrazinophthalazine in patients with arterial hypertension. J Clin Invest 34:115–120

    Article  PubMed  CAS  Google Scholar 

  139. Safar ME, Weiss YA, London GL, Milliez PL (1974) Short-term hemodynamic studies with prazosin. In: Cotton DWK (ed) Prazosin, evaluation of a new anti-hypertensive agent. Excerpta Medica, Amsterdam, pp 64–69

    Google Scholar 

  140. Sannerstedt R, Conway J (1970) Hemodynamic and vascular responses to antihypertensive treatment with adrenergic blocking agents. A review. Am Heart J 79:122–127

    Article  CAS  Google Scholar 

  141. Schmitt H, Schmitt H, Fenard S (1971) Evidence for an α-sympathomimetic component in the effects of Catapresan on vasomotor centres: antagonism by piperoxan. Eur J Pharmacol 14:98–100

    Article  PubMed  CAS  Google Scholar 

  142. Schneider KW (1968) Cardial-Hämodynamik im akuten Versuch, nach caronischer Behandlung und im Belastungstest mit St 155. In: Heilmeyer L, Holtmeier H-J, Pfeiffer EF (eds) Hochdrucktherapie: Symposion über 2-(2,6- dichlorophenylamino)-2-imidazohnhydrochlorid. Thieme, Stuttgart, pp 78–83

    Google Scholar 

  143. Scriabine A, Constantine JW, Hess HJ, McShane WK (1968) Pharmacological studies with some new antihypertensive aminoquinazolines. Experientia 24:1150–1151

    Article  PubMed  CAS  Google Scholar 

  144. Sellers EM, Koch-Weser J (1969) Proteine binding and vascular activity of diazoxide. Engl J Med 281:1141–1144

    Article  CAS  Google Scholar 

  145. Shand DG, Morgan DH, Oates JA (1973) The release of guanethidine and bethanidine by splenic nerve stimulation: A quantitative evaluation showing dissociation from adrenergic blockade. J Pharmacol Exp Ther 184:73–80

    PubMed  CAS  Google Scholar 

  146. Shand DG, Nies AS, McAllister RG, Oates JA (1975) A loadingmaintenance regimen for more rapid initiation of the effect of guanethidine. Clin Pharmacol Ther 18:139–144

    Google Scholar 

  147. Singh BN, Withlock RML, Combes RH, Williams FH, Harris EA (1976) Effects of cardiose- lective ß-adrenoceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma. Clin Pharmacol Ther 19:493–501

    PubMed  CAS  Google Scholar 

  148. Sjoerdsma A, Vendsaly A, Engelman K (1963) Studies on the metabolism and mechanism of acüon of methyldopa. Circulation 28:492–502

    PubMed  CAS  Google Scholar 

  149. Skinner C, Gaddu J, Pabner KNV (1976) Comparison of effects of metoprolol and propranolol on asthmatic airway obstruction. Br Med J 1: 504

    Article  PubMed  CAS  Google Scholar 

  150. Smith AJ (1965) Fluid retention produced by guanethidine. Changes in body exchangeable sodium, blood volume, creatinine clearance. Circulation 31:490–496

    PubMed  CAS  Google Scholar 

  151. Stenberg J, Holmberg S, Naets E, Vamauskas E (1968) The hemodynamic effects of Catapresan: Central circulation at rest; circulation at rest and during exercise. In: Heilmeyer L, Holtmeier HJ, Pfeiffer EF (eds) Hochdrucktherapie: Symposion über 2-(2,6-Dichlorophenylamino)-2-imi- dazolin-hydrochlorid. Thieme, Stuttgart, S68–75

    Google Scholar 

  152. Stokes GS, Graham RM, Gain JM, Davies PR (1977) Influence of dosage and dietary sodium on the first dose effect of prazosin. Br Med J 1:1507–1508

    Article  PubMed  CAS  Google Scholar 

  153. Stunkard A, Wertheüner L, Redisch W (1954) Studies on hydralacine; evidence for a peripheral site of action. J Clin Invest 33:1047–1053

    Article  PubMed  CAS  Google Scholar 

  154. Sundquist H, Anttila M, Arstila M (1974) Antihypertensive effect of practolol and Sotalol. Clin Pharmacol Ther 16:465–472

    PubMed  CAS  Google Scholar 

  155. Tarazi RC (1973) Diuretic drugs: mechanisms of antihypertensive action. In: Onesti G, Kim KE, Moyer JH (eds) Hypertension: mechanisms and management. Grune & Stratton, New York, pp 251–260

    Google Scholar 

  156. Tarazi RC (1973) Long-term hemodynamic effects of beta-adrenergic blockade in hypertension. In: Onesti G, Kim KE, Moyer JH (eds) Hypertension: Mechanisms and management. Grune & Stratton, New York London, pp 343–349

    Google Scholar 

  157. Tarazi RC, Dustan HP, Bravo EI, Niarchos AP (1977) Vasodilating drugs: Contrasting haemodynamic effects. Clin Sc Mol Med (Suppl 3) 51:575–578

    Google Scholar 

  158. Villarreal H, Exaire JE, Rubio V, Davila H (1964) Effect of guanethidine and bretylium tosylate on systemic and renal hemodynamics in essential hypertension. Am J Cardiol 14: 633–640

    Article  PubMed  CAS  Google Scholar 

  159. Weidmann P, Fuss O (1978) Medikamentöse Hypertoniebehandlung 1977. Empirische und rationale Gesichtspunkte. Schweiz Med Wochenschr 108:1–18

    PubMed  CAS  Google Scholar 

  160. Weil JV, Chidsey CA (1968) Plasma volume expansion resulting from interference with adrenergic function in normal man. Circulation 37:54–61

    PubMed  CAS  Google Scholar 

  161. Wollam GL, Gifford RW Jr, Tarazi RC (1977) Antihypertensive drugs: Clinical pharmacology and therapeutic use. Drugs 14:420–460

    Article  PubMed  CAS  Google Scholar 

  162. Wood AJ, Phelan EL, Simpson FO (1975) Cardiovascular effects of prazosin in normotensive and genetically hypertensive rats. Clin Exp Pharmacol Physiol 2:297–304

    Article  PubMed  CAS  Google Scholar 

  163. Woods JW, Pittman AW, Pulliam CC, Werk EE Jr, Waider W, Allen CA (1976) Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone. N Engl J Med 294:1137–1144

    Article  PubMed  CAS  Google Scholar 

  164. Zacharias FJ, Cowen KJ, Prestt J, Vickers J, Wall BG (1972) Propranolol in hypertension: A study of long term therapy 1964–1970. Am Heart J 83:755–761

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ellen Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum Innere Medizin und Kinderheilkunde der Universität, Steinhövelstraße 9, 7900, Ulm, Deutschland

    Julian Rosenthal

Rights and permissions

Reprints and permissions

Copyright information

© 1980 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Weber, E. (1980). Klinische Pharmakologie der antihypertensiven Pharmakotherapie. In: Rosenthal, J. (eds) Arterielle Hypertonie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-96451-0_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-96451-0_31

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-96452-7

  • Online ISBN: 978-3-642-96451-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation